Xofluza for Acute Uncomplicated Influenza

News
Article
Drug Topics JournalDrug Topics March 2019
Volume 163
Issue 3

Xofluza Product Boxes

Xofluza (baloxavir marboxil, Genetech)

Indications: acute uncomplicated influenza in patients 12+, <48hr symptomatic

Dosage:

  • 40-80kg body = 40 mg

  • 80kg+ = 80 mg

Contraindications: history of hypersensitivity to baloxair marboxil or any of its ingredients

Click here for more prescribing information

Download Issue PDF
Articles in this issue
Grief
Coping with Patient Death
Clock
Opinion: Why Change Is Like a Hemorrhoidectomy
Pharmacist Behind Counter
Pharmacists Want More Time with Patients
Health System
The Pros and Cons of Switching to a Health System
Elderly Couple in Park
Early Planning is Key to Retirement and Succession
Dietary Supplements
Dietary Supplements Need Evidence and Evaluation
Coffee Cups
Reconnect to Reinvigorate
Book shelves
Pharmacy Education for the 21st Century
March Cover Image
How to Achieve Balance in Work and in Life
Slippers
Case Studies in Stability
Patient Doctor Medication
Opinion: Avoiding "White Coat Marketing" Accusations
Xofluza Product Boxes
Xofluza for Acute Uncomplicated Influenza
Recent Videos
Related Content
FDA Updates Veozah Label With Boxed Warning for Rare But Serious Liver Injury

FDA Updates Veozah Label With Boxed Warning for Rare But Serious Liver Injury

Lauren Biscaldi, MS, Managing Editor
December 18th 2024
Article

The patient’s symptoms gradually resolved after discontinuing fezolinetant therapy.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Roundup: ATX101 Gains Breakthrough Therapy Designation, Stelara Biosimilar Approval

FDA Roundup: ATX101 Gains Breakthrough Therapy Designation, Stelara Biosimilar Approval

Killian Meara
December 6th 2024
Article

Catch up on important FDA news from the week of December 2.

Influenza Vaccine Least Effective for Children Facing Secondary Infection

Influenza Vaccine Least Effective for Children Facing Secondary Infection

Brian Nowosielski
December 2nd 2024
Article

Researchers addressed vaccine effectiveness for individuals with direct household contacts that reported influenza.

FDA Approves Acoramidis for ATTR-CM

FDA Approves Acoramidis for ATTR-CM

Lauren Biscaldi, MS, Managing Editor
November 25th 2024
Article

This approval marks the availability of the first near-complete stabilizer of transthyretin.

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

Killian Meara
November 12th 2024
Article

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

© 2024 MJH Life Sciences

All rights reserved.